Syncromune Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
33
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$145M
- Investors
-
1
Syncromune General Information
Description
Developer of intratumoral immunotherapy designed to treat metastatic solid tumor cancers. The company's immunotherapy utilizes intratumoral sync technology to synchronize the timing and location of tumor antigen release with the functional activation of immune cells, enabling patients to power a personalized autologous vaccine with their cancer antigens.
Contact Information
Website
www.syncromune.comCorporate Office
- 2919 East Commercial Boulevard
- Suite 200
- Fort Lauderdale, FL 33308
- United States
Corporate Office
- 2919 East Commercial Boulevard
- Suite 200
- Fort Lauderdale, FL 33308
- United States
Syncromune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 11-May-2026 | $145M | Completed | Generating Revenue | ||
| 1. Debt - General | 10-Feb-2022 | Completed | Generating Revenue |
Syncromune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A-2 | ||||||||
| Series A-3 | 4,375,543 | $0.000010 | $2.74 | $2.74 | 1x | $2.74 | 5.63% | |
| Series A-4 | 9,629,243 | $0.000010 | $2.08 | $2.08 | 1x | $2.08 | 12.38% |
Syncromune Patents
Syncromune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025250751-A1 | System to create cellular lysis and deliver fluids intratumorally | Pending | 05-Apr-2024 | ||
| US-20250312080-A1 | System to create cellular lysis and deliver fluids intratumorally | Pending | 05-Apr-2024 | ||
| US-20260034297-A1 | System to create cellular lysis and deliver fluids intratumorally | Pending | 05-Apr-2024 | ||
| WO-2025213133-A1 | System to create cellular lysis and deliver fluids intratumorally | Pending | 05-Apr-2024 | ||
| AU-2023281615-A1 | A method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients | Pending | 01-Jun-2022 | A61K39/39541 |
Syncromune Signals
Syncromune Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Wasatch Health | Growth/Expansion | Minority |
Syncromune FAQs
-
When was Syncromune founded?
Syncromune was founded in 2020.
-
Where is Syncromune headquartered?
Syncromune is headquartered in Fort Lauderdale, FL.
-
What is the size of Syncromune?
Syncromune has 33 total employees.
-
What industry is Syncromune in?
Syncromune’s primary industry is Drug Discovery.
-
Is Syncromune a private or public company?
Syncromune is a Private company.
-
What is the current valuation of Syncromune?
The current valuation of Syncromune is .
-
What is Syncromune’s current revenue?
The current revenue for Syncromune is .
-
How much funding has Syncromune raised over time?
Syncromune has raised $155M.
-
Who are Syncromune’s investors?
Wasatch Health has invested in Syncromune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process